Thermo Fisher expands COVID-19 therapies, vaccines

By The Science Advisory Board staff writers

July 20, 2020 -- Thermo Fisher Scientific is expanding the development and production of COVID-19 vaccines, therapies, and additional treatments.

The U.S. Biomedical Advanced Research and Development Authority is providing funding to the company for expanded manufacturing capacity for sterile injectables, which can be used to fill a high volume of vaccine doses. Additionally, the company is assisting with several vaccine programs that are currently under clinical development.

Thermo Fisher is supporting over 200 COVID-19 related projects with an investment of over $800 million. This work has provided expanded capacity for developing new and existing therapies such as antiviral drugs to accelerate development and delivery to the clinic. Moreover, the company's "site to patient" program works to ensure that clinical trial participants have uninterrupted access to life-saving investigational drug shipments without having to visit a clinic.

Copyright © 2020

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for